|Assessment Status||Assessment Process Complete|
|Indication||For the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.|
|Rapid review commissioned||06/11/2015|
|Rapid review completed||30/11/2015|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
|Full submission received from Applicant||07/03/2016|
|NCPE assessment completed||08/07/2016|
|NCPE assessment outcome||Reimbursement Recommended|
The NCPE considers valsartan/sacubitril (Entresto) cost-effective for the current licensed indication and recommends reimbursement.
The HSE has approved reimbursement following confidential price negotiations October 2017.